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Abstract
Activin and inhibin are important local modulators of theca cell steroidogenesis in the ovary. Using a serum-free primary
theca cell culture system, this study investigated the effects of inhibin on theca cell androgen production and expression
of steroidogenic enzymes. Androstenedione secretion from theca cells cultured in media containing activin, inhibin and
follistatin was assessed by RIA over 144 h. Activin (1–100 ng/ml) suppressed androstenedione production. Inhibin
(1–100 ng/ml) blocked the suppressive effects of added activin, but increased androstenedione production when added
alone, suggesting it was blocking endogenous activin produced by theca cells. Addition of SB-431542 (activin receptor
inhibitor) and follistatin (500 ng/ml) increased androstenedione production, supporting this concept. Infection of theca
cells with adenoviruses expressing inhibitory Smad6 or 7 increased androstenedione secretion, conﬁrming that the
suppressive effects of activin required activation of the Smad2/3 pathway. Activin decreased the expression levels of
steroidogenic acute regulatory protein (STAR), whereas STAR expression was increased by inhibin and SB-431542,
alone and in combination. CYP11A was unaffected. The expression of CYP17 encoding 17a-hydroxylase was unaffected
by activin but increased by inhibin and SB-431542, and when added in combination the effect was further enhanced. The
expressionof 3b-hydroxysteroid dehydrogenase (3b-HSD) was signiﬁcantly decreasedby activin,while inhibin aloneand
in combination with SB-431542 both potently increased the expression of 3b-HSD. In conclusion, activin suppressed
theca cell androstenedione production by decreasing the expression of STAR and 3b-HSD. Inhibin and other blockers of
activin action reversed this effect, supporting the concept that endogenous thecal activin modulates androgen production
in theca cells.
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Introduction
Female fertility relies on a tightly controlled balance
of hormonal signals and cellular interactions that
result in the successful production of a mature oocyte
for fertilization. Of these hormones, estradiol is a vital
component required for oocyte maturation (Tesarik &
Mendoza 1995). It is synthesized in granulosa cells
from androgen precursors produced by theca cells
that surround developing antral follicles, and is
produced in increasing quantities by the growing
follicle as development reaches the preovulatory stage
(Young & McNeilly 2010). Before the expression of
aromatase in granulosa cells, follicles are exposed to
varying levels of androgens derived from thecal cells
largely under the control of LH.
In vitro, testosterone inhibits meiotic maturation of
the oocyte and subsequent embryo development
(Laufer et al. 1984, Anderiesz & Trounson 1995). This
negative effect of androgens would potentially be
neutralized in vivo by expression of aromatase in the
cumulus granulosa cells surrounding the oocyte in the
preovulatory follicle, thus reducing exposure to these
potentially damaging effects of excess testosterone
and androgens.
In rodents, androgens not only can induce follicular
atresia (Hillier & Ross 1979, Daniel & Armstrong
1986, Billig et al. 1993) but also have been shown to
promote follicular development (Murray et al. 1998)
and upregulate FSH-receptor expression in granulosa
cells in culture (Tetsuka & Hillier 1997). In primates,
intermittent exposure to androgens in normal female
monkeys resulted in accelerated early stages of ovarian
follicle development with reduced granulosa cell
atresia and increased thecal cell mass, and enhanced
granulosa cell FSH-receptor expression (Vendola et al.
1998, Weil et al. 1999). In contrast, chronic exposure
led to intermittent or absent menstrual cycles (Billiar
et al. 1985, Faiman et al. 1988). Thus, excess androgen
production at an inappropriate time could directly
affect the rates of follicle activation and lead to
premature loss of primordial follicles.
In polycystic ovary syndrome (PCOS), follicle
development is stalled, and a major characteristic is
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an intrinsic ability of thecal cells to produce increased
levels of androgens (Gilling-Smith et al. 1994, 1997,
Nelson et al. 1999, 2001, Nelson-Degrave et al. 2005). It
has been suggested that androgen-induced expression
of insulin-like growth factor 1 (IGF1) and its receptor in
early growing follicles may predispose thecal cells to
produce more androgens (Vendola et al. 1999), while
MEK/ERK phosphorylation has been shown to be
decreased in thecal cells from patients with PCOS
compared with normal subjects (Nelson-Degrave et al.
2005). This excess androgen itself has been implicated
in the failure of follicles to continue to grow in PCOS.
In spite of these studies, the modulation of androgen
secretion by thecal cells from small antral stages as
follicles develop into a preovulatory follicle during
normal reproductive cycles is still unclear (Young &
McNeilly 2010). Previous studies have shown that both
BMPs (Glister et al. 2005, Campbell et al. 2006) and
activin (Hillier et al. 1991a) can reduce androgen
secretion from primary cultures in vitro. Furthermore, it
was shown that inhibin alone could ‘stimulate’ andro-
gen production and also neutralize the effects of added
activin by human theca cells (Hillier et al. 1991b).
However, there is no evidence that inhibin has a
receptor coupled to any second messenger signaling
pathway, but instead binds to betaglycan and the type 2
activin receptor to block the effects of activins (Lewis
et al. 2000). Given that this is the case, the real effects of
inhibin would then be to block the intrinsic inhibitory
effects of activins that presumably are being produced
by the thecal cells themselves. In this study, we have
sought to clarify the role of inhibin on thecal cell
androgen production by normal thecal cells main-
tained in primary cultures in conditions that prevent
luteinization, thus mimicking the situation during
normal follicle development. Using adenoviral vectors,
follistatin and a speciﬁc chemical activin receptor
blocker (SB-431542), we have shown that inhibin acts
only as an activin inhibitor, rather than ‘stimulating’
androgen production. Instead inhibin removes the
activin-induced brake on androgen production.
Materials and methods
Primary theca cell culture
Ovaries were obtained from sheep throughout the year
and transferred to the laboratory in Medium 199
containing 20 mmol/l HEPES, 100 kIU/l penicillin,
0.1 ng/ml streptomycin and 1 mg/l amphotericin
(Fungizone; all supplied by Sigma–Aldrich). Small
follicles (!3.5 mm in diameter) were dissected from
ovaries in Dulbecco’s PBS without calcium or mag-
nesium, with particular attention given to removal of all
extraneous stromal tissues surrounding the thecal
layers. Follicles were then hemisected, and washed
vigorously using a 1 ml syringe, ﬂushing repeatedly to
separate granulosa cells from the thecal cells as
described previously (Campbell et al. 1996). The thecal
cells were then dispersed in an enzyme mixture
containing 10 ml PBS, 5 g/l collagenase, 1 g/l hyalur-
onidase, 1 g/l protease and 0.001% donor calf serum
(vol/vol) for w10 min at 37 8C with gentle agitation.
The reaction was stopped by addition of 2 ml FCS, and
cells were then washed by centrifugation at 800 g for
5 min and resuspended in culture media (DMEM-F12
with 100 kIU/l penicillin, 0.1 mg/l streptomycin,
3 mmol/l L-glutamine, 0.1% BSA (w/vol), 2.5 mg/l
transferrin, 4 mg/l selenium, 10 ng/ml bovine insulin
and 10 ng/ml LR3 IGF1). Ovine LH (code #AFP 8614B-
NHPP-NIDDK supplied by Dr A Parlow, NHPP, Harbor-
UCLA, Torrance, CA, USA) was also added to all culture
media at 0.1 ng/ml ovine LH, unless otherwise stated.
The cell pellets were then resuspended in culture
media, and after a further wash, the number and
viability of the cells were estimated using Trypan Blue
exclusion. Cell viability was routinely more than 95%.
Cells were plated in 96-well plates at 75 000 cells in a
total of 200 ml media/well. Various concentrations and
combinations of ligand and chemical treatments were
added to the media in quadruplicate, and the exact
details are given in the ‘Results’section. Activin A (code
#338-AC) and follistatin (code #669FO/CF) were
obtained from R & D Systems (Abingdon, Oxon, UK),
inhibin A was from NIBSC (code #91/624, Hertford-
shire, UK) and SB-431542 was supplied by Sigma–
Aldrich. Cells were cultured under standard culture
conditions consisting of a humidiﬁed atmosphere with
5% CO2 at 37 8C. For hormone analysis, cells were
cultured for up to 6 days and the media changed every
48 h and stored at K20 8C for analysis at a later stage.
At the end of the culture period, the cell viability was
determined by Neutral Red dye uptake as described
elsewhere (Campbell et al. 1996).
Adenovirus transfection
Recombinant adenoviruses were constructed from
pcDNA3–Smad6, and pcDNA3–Smad7 expression
plasmids obtained from Dr P Ten Dijke (The Nether-
lands Cancer Institute, Amsterdam, The Netherlands),
as described previously (Fujii et al. 1999, Nakao et al.
1999), and were a generous gift from Dr Aristidis
Moustakas (Ludwig Institute for Cancer Research,
Uppsala, Sweden). Thecal cells were isolated and
dissociated enzymatically as previously described and
were plated in culture media under standard culture
conditions at 75 000 cells/well and incubated over-
night to allow cell attachment. The following day,
all media were removed, infection of recombinant
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and 100 plaque-forming units (pfu)/cell overnight, and
then the following day, the cells were resuspended in
200 ml culture mediaGappropriate ligands/treatments.
The culture media were then changed every 48 h up to
144 h, and stored at K20 8C for RIA.
Steroid assays
Concentrations of androstenedione were determined
from non-extracted cell culture media by a previously
described RIA method (Campbell et al. 1998). The
sensitivity of the androstenedione assay was w5 pg/ml,
and the inter- and intra-assay variation was !15%.
Quantitative RT-PCR
Thecal cell cultures for RNA collection were established
as described above, but were plated at w750 000
cells/well in six-well plates and left to attach overnight.
Treatmentswereadded infreshmediathe followingday
and left to incubate under standard culture conditions.
After 24 h, another dose of ligand was added to the
same media, and then again at 48 h. After the ﬁnal dose
was added at the 48 h time point, cells were incubated
for a further 1 h, then media removed and stored at
K20 8C for RIA, and cells lysed and RNA extracted
using the Qiagen RNeasy Micro RNA extraction kit.
RNA concentration and purity (A260/A280 ratio) were
measured using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientiﬁc). RNA was stored at K80 8C
until cDNA was synthesized from 200 ng total RNA per
reaction using Superscript VILO cDNA synthesis kit
(Invitrogen) in a 20 ml reaction.
Primer sets for expression analysis were designed
to amplify short regions of the target genes crossing
an intron/exon boundary and are listed in Table 1.
The primers were pre-validated using conventional PCR
and the product was sequenced to conﬁrm authenticity.
Quantitative RT-PCR (qRT-PCR) was carried out using
Power SYBR Green (Applied Biosystems), whereby
the primer efﬁciency was determined by generating
standard curves. A 10 ml ﬁnal reaction volume was
prepared using 1 ml synthesized cDNA, 2! Power SYBR
Green PCR Master Mix, 5 mM primer pairs, and
nuclease-free water. The qRT-PCR cycling program
consisted of a denaturing step (95 8C for 10 min),
annealing and extension step (95 8C for 15 s and 60 8C
for 1 min) repeated 40 times, and a dissociation step
(95 8C, 60 8C and 95 8C for 15 s each), using a real-time
thermal cycler from Applied Biosystems (ABI-7500).
Each sample was measured in duplicate, and negative
controls included a reaction using cDNA prepared
leaving out reverse transcriptase and a reaction
substituting cDNA with nuclease-free water. The relative
expression level of each target gene to GAPDH was
quantiﬁed by the DDCt method. Data were presented as
averageGS.E.M. and the statistical analysis was per-
formed using the Student’s t-test. P values !0.05 were
regarded as signiﬁcant, and levels of signiﬁcance were
indicated on graphs for each gene analyzed.
Statistical analysis
For each cell culture experiment, cells from at least four
sheep were pooled and treatments carried out in
quadruplicate. The signiﬁcance of treatment effects
was determined by ANOVA, and individual compari-
sons between treatments were made using Student’s
t-test. All hormone data were expressed as picograms
of hormone per microliter of cell culture media.
Results
In this study, activin receptors (types IA, IB, IIA and
IIB), Smad2/3, and the putative inhibin co-receptor
betaglycan (transforming growth factor (TGF) bRIII)
were identiﬁed in ovine theca and granulosa cells
during folliculogenesis (data not shown).
Activin suppressed androgen secretion
The effects of activin A at 1, 10 and 100 ng/ml on thecal
androgen production are shown in Fig. 1A. Activin A
was a potent inhibitor of androstenedione production
from ovine thecal cells in vitro and was highly effective at
the lowest dose tested (1 ng/ml). Viability evaluated by
Neutral Red assay on completion of culturing at 144 h
Table 1 Forward and reverse primer sequences for quantitative
RT-PCR and respective amplicon size
Gene
(accession) Nucleotide sequence (50–30)
Product
size (bp)
GAPDH (NM_001034034) 229
Forward GGCGTGAACCACGAGAAGTATAA
Reverse AAGCAGGGATGATGTTCTGG
STAR (NM_001009243) 194
Forward GCATCCTCAAAGACCAGGAG
Reverse CTTGACACTGGGGTTCCACT
CYP17 (NM_001009483) 215
Forward AGACATATTCCCTGCGCTGA
Reverse GCAGCTTTGAATCCTGCTCT
3b-HSD (NM_001135932) 200
Forward GGAGACATTCTGGATGAGCAG
Reverse TCTATGGTGCTGGTGTGGA
CYP11A (NM_001093789) 172
Forward CAGGAGGCAGTAGAGGATGC
Reverse CAACGTCCCTCCAGAACTGT
Id1 (NM_001097568) 151
Forward TCTGGGATCTGGAGTTGGAG
Reverse ATACGATCGTCCGCTGGAA
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Analyses also showed that theca cells maintained
androgen production during the last 48 h culture
period, indicating good health and steroidogenic
capabilities. Furthermore, progesterone output
measure by RIA (data not shown) remained at initial
control levels throughout the culture period, indicating
a lack of luteinization in the culture conditions as
expected (Campbell et al. 1998).
Inhibin increased androgen production
Inhibin increased (P!0.001) androstenedione pro-
duction from theca cells cultured in vitro (Fig. 1B).
Results show a potent response to inhibin, which was
highly effective at the lowest dose evaluated (1 ng/ml).
Inhibin added alone is likely to act by blocking the
suppressive effects of endogenously produced activin,
and possibly also acts on BMPs that may be produced by
theca cells in vitro (Wiater & Vale 2003).
Inhibin blocked the suppressive effects of activin
on theca steroidogenesis
Inhibin blocked the suppressive effects of added
activin on theca androstenedione production at
144 h but not at 96 h (Fig. 2). The effects of inhibin
became more signiﬁcant over time, and on completion
of the culture, inhibin antagonized (P!0.001) activin
suppression.
Activin receptor inhibitor stimulated steroidogenesis
The small molecule inhibitor SB-431542 is a potent
and speciﬁc inhibitor of activin receptors type IB
(ALK4), TGFbRI (ALK5) and activin receptor type IC
(ALK7) (Inman et al. 2002). In this experiment, the
effects of this chemical activin receptor inhibitor were
compared with those of inhibin. The manufacturer’s
instructions indicate that 10 mM SB-431542 is required
for complete ablation of Smad2 phosphorylation by
activin receptors IB, IC and TGFbRI. A dose response
was therefore established from 0.1t o1 0mM, and the
total androstenedione produced over time in culture
is shown in Fig. 3. Results showed that SB-431542
increased androstenedione secretion at 0.1–2 mM,
but had no effect from 5 to 10 mM( d a t an o t
shown). Cell viability assessed on completion of the
144 h culture period showed that at concentrations
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Figure 1 Androstenedione production in theca cell cultures (A)
in the presence of 0–100 ng/ml activin A and (B) effects of inhibin A
on theca androstenedione production. Cell culture media were
replacedevery48 handandrostenedionesecretedintospentmedia
wasevaluatedbyRIA.ResultsshowaverageGS.E.M.Dataprovided
are representative of at least four experiments, of which each
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pool), *P!0.05 and ***P!0.001 compared with the control group.
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Figure 2 Androstenedione production from theca cells in the
presenceofactivin(10 ng/ml),inhibin(100 ng/ml)and bothfactors
added together. Results give data of the averageGS.E.M. of four
replicate wells of pooled theca cells from four sheep, androste-
nedione was measured by RIA. *P!0.5 and ***P!0.001
compared with the control group.
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ing that SB-431542 had a detrimental effect on these
cells (data not shown).
SB-431542 was added at doses ranging from 0.1t o
2 mM to maintain cell viability. Inhibin was used in
combination with SB-431542 to evaluate whether the
level of androgen secreted from cells was equal in cells
treated with either inhibitor. If inhibin was merely
causing androgen production by blocking the suppres-
sive effects of activin, then the expected result would be
equivalent to that observed when the chemical activin
receptor inhibitor was present. Interestingly, in this
experiment, the level of androstenedione secretion was
greater in cell cultures treated with both inhibin and
SB-431542 (Fig. 3).
Follistatin inhibited activin suppression
Follistatin is a known antagonist of TGFb superfamily
members, including activin and BMPs, and was
originally identiﬁed from the follicular ﬂuid of ovarian
follicles (Ueno et al. 1987). Follistatin (500 ng/ml) was
added to cultures and androstenedione production
measured (Fig. 3). The results show that the addition of
follistatin increased androgen accumulation over 144 h
in culture (P!0.001).
Inhibitory Smads 6 and 7 increased androgen
production
Smads 6 and 7 are intracellular signaling molecules that
inhibit the signal transduction of BMP (Smad1/5/8),
or BMP and activin (Smad2/3) signaling respectively.
These inhibitory factors were transfected into theca
cultures using adenoviruses to manipulate Smad signal
transduction speciﬁcally. To establish the rate of
infection required, the adenovirus construct was titred
across concentrations from 10 to 100 pfu/cell seeded
(Fig. 4A). Results indicated that 10 pfu/cell was
sufﬁcient to infect cells, and that at higher concen-
trations theca cell viability decreased. Overexpression
of Smad6 or 7 by infecting cells at 10, 50 and 100 pfu/
cell resulted in increased androstenedione production
from theca cells in culture over two consecutive 48 h
periods postinfection (Fig. 4A). It is not unexpected
that the effects of Smad7 are more pronounced than
those of Smad6 given that Smad7 inhibits both Smad1/
5/8 and Smad2/3 (rather than just Smad1/5/8 for
Smad6). BMPs have been previously shown to suppress
androstenedione production in bovine and ovine theca
cultures (Glister et al. 2005, Campbell et al. 2006), so
blocking BMP signaling with Smad6 would remove this
suppression which is presumably due to BMPs being
produced endogenously by the thecal cells themselves.
Adenovirus transfections were carried out at 10 pfu/
cell thereafter.
As expected, when activin was added to cells over-
expressing Smad6, the suppressive effects of activin
were not markedly altered. However, when Smad7 was
overexpressed, activin was unable to suppress androgen
production (P!0.001; Fig. 4B). Inhibin effects were not
affected by overexpression of either Smad6 or 7.
Activin and inhibin modulate expression of genes
required for steroidogenesis
Given that activin and inhibin modulate androstene-
dione production from ovine theca cells in culture, we
assessed the effects of these factors on the expression
levels of components of the steroidogenic pathway
(Fig. 5). The expression of steroidogenic acute
regulatory protein (STAR), which is responsible for
transportation of cholesterol esters into the mito-
chondria for initiation of steroidogenesis, was dec-
reased in the presence of added activin (50 ng/ml),
and increased by SB-431542 alone (2 mM) and in
combination with inhibin (100 ng/ml; P!0.05). Acti-
vin alone did not affect the expression of CYP17
encoding 17a-hydroxylase (17aOH), whereas it was
increased by inhibin (P!0.05) and SB-431542
(P!0.001), and when added in combination, the
stimulatoryeffectwasfurtherenhanced(P!0.001).The
expression level of 3b-hydroxysteroid dehydrogenase
100
40
0
***
***
***
***
***
*
*
**
80
60
20
Treatment
SB-431542 µM
Inhibin
Inhibin
Control
0·1 2 1 2
FS 1
0·1
A
n
d
r
o
s
t
e
n
e
d
i
o
n
e
 
(
p
g
/
µ
l
)
Figure 3 Androstenedione secretion from theca cells in the
presence of inhibin (10 ng/ml), SB-431542 (0.1–2 mM), or both
SB-431542 and inhibin (10 ng/ml), and follistatin (FS, 500 ng/ml)
over an accumulative period of 144 h. Data presented are the
averageGS.E.M. of four replicate wells, all from the same pool of
cells (nZ4 sheep pooled). *P!0.05, **P!0.01 and ***P!0.001
compared with the control group. The statistical signiﬁcance of
SB-431542 alone and together with inhibin is also shown above
each treatment group as *P!0.05.
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activin, while inhibin alone (P!0.01) and in com-
bination with SB-431542 (P!0.001) both increased the
expression of 3b-HSD. There were no signiﬁcant effects
on the expression of cytochrome P450, family 11,
subfamily A and polypeptide 1 (CYP11A), indicating
that the effects of activin and inhibin are targeted
primarily to the expression of 3b-HSD.
Expression of inhibitor of DNA-binding (ID) genes
ID1 expression levels were signiﬁcantly reduced in the
presence of activin, inhibin and SB-431542 (P!0.05),
but the levels of ID2 did not change signiﬁcantly for any
treatment group. ID3 and ID4 mRNA levels were below
detection levels (data not shown).
Discussion
There is contradictory evidence for a role of activin in
follicle development, where some studies have shown
stimulatory effects (Li et al. 1995, Smitz et al. 1998,
Liu et al. 1999, Zhao et al. 2001, Thomas et al. 2003,
McLaughlin et al. 2010), while others suggest activin
inhibits development (Mizunuma et al. 1999, Ding et al.
2010), prevents luteinization (Myers et al. 2008), or has
no effect at all (Fortune et al. 2000). Moreover, the
concept of activin acting alone is far removed from the
in vivo situation where many other factors are present
that can antagonize and modulate the efﬁciency of
activin signaling.
Studies on ovarian somatic cells have been conducted
using media containing serum, which have been shown
toinduceluteinizationofcells,thuschangingbiological
functionality to principally the secretion of pro-
gesterone rather than androgens (Hillier et al. 1991b,
Shukovski et al. 1993, Wrathall & Knight 1995). In this
study, serum-free conditions were employed, and theca
cells were cultured for a maximum of 144 h in the
presence of low-dose LH to maintain androgen ster-
oidogenic capacity. This study extends on previous
ﬁndings in luteinized theca cells that activin A
suppresses androgen production from thecal cells
cultured in vitro without affecting cell viability (Hsueh
etal.1987,Hillier&Miro1993,Wrathall&Knight1995).
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bioactivity is inhibin, which is produced by granulosa
cells once follicles reach the preantral stage of
development (Roberts et al. 1993). It has been unclear
whether inhibin acts by simply blocking binding of
activin and BMPs to their receptors or it can elicit its
biological effects through an unidentiﬁed mechanism
not involving antagonism of activin/BMP receptors
since no signaling pathways have been identiﬁed with
inhibin bioactivity (Bernard et al. 2001, 2002). Associ-
ation of inhibin with the membrane-anchored proteo-
glycan, betaglycan (also known as TGFbRIII), has been
shown to increase the afﬁnity of inhibin binding to
activin typeII receptors (Lewis et al. 2000). However, itis
unclear if inhibin can elicit any signaling through
betaglycan in a manner similar to TGFb2 that utilizes
the small cytoplasmic domain of this receptor for
downstream signal transduction (Blobe et al. 2001).
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Figure 5 The expression of steroidogenic acute regulatory protein (STAR), 17a-hydroxyl-
ase (CYP17), 3b-hydroxysteroid dehydrogenase (3b-HSD), cholesterol side-chain
cleavagecytochromeP450(CYP11A)andinhibitorofDNAbinding1(ID1)wasassessedin
thecacellsculturedalone,orinthepresenceofactivin(50 ng/ml),inhibin(100 ng/ml)and/or
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each well at 24 and 48 h and then an hour before RNA isolation. Data are the average
GS.E.M. forfour replicateexperiments(eachexperiment fromapool ofcellsharvestedfrom
four to ﬁve sheep) containing four replicate wells per treatment. *P!0.05, **P!0.01 and
***P!0.001 were assessed by Student’s t-tests compared with the control group.
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increased approximately ﬁvefold as bovine follicles
grew and decreased by 50% when follicles reached
the ﬁnal stages of development, indicating an import-
ant role during the stages of development (Glister et al.
2010). Betaglycan is also found in granulosa and thecal
cells of sheep follicles (data not shown).
In this study, inhibin had a potent and robust
stimulatory effect on androstenedione production
when added to cell culture media alone. Furthermore,
it blocked the suppressive effects of activin added to
culture medium, conﬁrming previous ﬁndings (Hillier
et al. 1991b, Hillier & Miro 1993, Wrathall & Knight
1995, Campbell & Baird 2001). The observation that
inhibin-treated cells produce considerably more andro-
gen than cells with no inhibin added indicates that
theca cells might produce activin and/or BMPs that
act in an autocrine manner to maintain the level of
androgen production at a basal level. The production
of activin bA subunit was investigated in these cultures,
and it was conﬁrmed that theca cells produce activin bA
(data not shown).
Follistatin is produced by granulosa cells and is
abundant in follicles as soon as two layers of granulosa
cells have developed, and is maintained at high levels of
expression through all stages offollicle development up
to ovulation (Shimasaki et al. 1989, Nakatani et al. 1991,
Roberts et al. 1993, Braw-Tal et al. 1994, Tisdall et al.
1994, Izadyar et al. 1998, Sidis et al. 1998, Silva & Knight
1998). While follistatin was shown to have only a 10%
afﬁnity for BMPs as for activins (Glister et al. 2004), it
was shown to reverse the suppressive effects of added
activin A, TGFb and BMP4/6/7 on thecal androgen
production (Hsueh et al. 1987, Hillier & Miro 1993,
Wrathall & Knight 1995, Cortvrindt et al. 1997, Glister
et al. 2005). In our study, when added in excess,
follistatin alone increased androgen production from
theca cells, supporting the concept that theca cells
produce activins/BMPs endogenously in vitro.
To further address this concept, we used the non-
signaling chemical activin receptor inhibitor SB-431542
as a comparative measure against inhibin (Bak et al.
2009). Androstenedione production was enhanced
from theca cultures to levels similar to those produced
by inhibin-treated cells, and an additive effect was
observed when inhibin and SB-431542 were added in
combination. This may be due to a dynamic mechanism
of inhibin action compared with the binding of the
chemical compound, or the fact that inhibin also
interferes with BMP signaling in addition to blocking
activin signaling since SB-431542 does not appear to
block BMPs effectively.
Intracellular inhibitory Smads were utilized to
investigate signaling mechanisms. The overexpression
of inhibitory Smads 6 and 7 alone (Fujii et al. 1999,
Nakao et al. 1999, Kaivo-Oja et al. 2003) resulted in
increased androstenedione production from theca
cultures over time. Moreover, the inhibition of signal-
ing by Smad7 was observed to have a more potent effect
than that caused by Smad6. This result is logical given
that Smad6 blocks BMP signaling through Smad1/5/8,
whereas Smad7 blocks both Smad1/5/8 and Smad2/3
pathways. Of importance, these results show that by
blocking activin and BMP signal transduction intra-
cellularly, theca cells produce greater amounts of
androstenedione than control cells over time.
As expected, since Smad6 affects the Smad1/5/8
pathway, it had no effect on the ability of activin A to
suppress androstenedione production and equally did
not block the stimulatory effects of inhibin. Activin
signaling was blocked by the overexpression of Smad7
but not by Smad6. Inhibin had an additive effect on
androstenedione production when Smad6 or 7 was
overexpressed. Taken together, these studies indicate
that inhibin acts similar to Smad signaling inhibitors
Smad6 or 7 by blocking Smad signal transduction and
increasing androgen production.
While activin and inhibin modulate theca cell
steroidogenesis, it has not been clear how this is
achieved. Gene expression analyses showed that activin
suppressed expression levels of STAR and 3b-HSD,
whilst inhibin and SB-431542 induced expression of
CYP17 and 3b-HSD. A previous study using a CYP17
promoter–luciferase reporter system in the H295R cell
line in vitro suggested that Smad3 directly inhibited
CYP17 promoter activity (Derebecka-Holysz et al. 2008),
but this was not replicated in this study with activin-
induced Smad2/3 in primary thecal cells. The most
potent and signiﬁcant effects of activin, inhibin and
SB-431542 were found on the expression levels of
3b-HSD, indicating an important role for these factors
in modulating 3b-HSD abundance. 3b-HSD is required
for synthesis of both progesterone and androgens in
theca cells, and 17aOH is required for androgen
production. If inhibin stimulates or removes an
activin-induced inhibition of 3b-HSD expression, then
it would make sense that more progesterone would be
produced compared with androgens since the substrate
pregnenolone is being used to make progesterone,
therefore limiting the substrate available to 17aOH for
17-hydroxypregnenolone synthesis. However, past
research has not shown any effect of inhibin on
progesterone secretion from theca cells cultured in
media containing 5% FCS (Hillier et al. 1991b),
which may be due to luteinization. Testosterone is
synthesized from androstenedione in theca cells by
the enzyme 17b-hydroxysteroid, which has not been
assessed in these studies, as this enzyme is not thought
to be regulated by activins/inhibins due to the lack of
response in testosterone levels in these and other
studies (Shukovski et al. 1993). Furthermore, in this
study, activin, inhibin, SB-431542, Smad6 or 7 did not
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Expression of the inhibitor of DNA-binding protein
genes (ID1–4) was assessed and the results agreed with
previous studies on granulosa cells from sheep follicles
(Hogg et al. 2010). Levels of mRNA encoding ID1 were
suppressed in the presence of activin A, but no changes
in ID2 expression were observed while ID3 and ID4 were
undetectable. In our previous study (Hogg et al. 2010),
activin decreased ID3 expression in granulosa cells;
moreover, this study also provided evidence that in
atretic follicles, ID3 and ID4 expression was partial or
absent. Since primary theca cells were cultured for a
short period of time and cells remained healthy and
viable, changes in ID2 were not expected. In other
experiments, BMPs increased ID1–4 expression in theca
cultures (data not shown). BMPs are functional in
the sheep follicle as evidenced by the presence of
p-Smad1/5/8 in theca and granulosa cells (Hogg et al.
2010) and from previous in vitro studies on bovine
thecal cells (Glister et al. 2010) and also our current
results using Smads 6 and 7, both of which inhibit BMP
signaling. Thus, it may be that in our culture system,
any endogenous BMPs that are being produced
are insufﬁcient to maintain ID1–4 expression or are
counteracted by the endogenous activin being pro-
duced by the theca cultures themselves. The failure of
inhibin and the activin receptor blocker SB-431542 to
maintain or increase ID2 requires further investigation.
In humans, inhibin B is the predominant form of
inhibin present during the follicular phase of the cycle,
and inhibin A in the luteal phase (Groome et al. 1996).
However, inhibin B is not found in sheep ovaries. So,
these studies were carried out using only inhibin A
(McNeilly et al. 2002). In patients diagnosed with PCOS,
studies have shown that circulating inhibin B levels were
higher while activin A was lower in the follicular phase
(Anderson et al. 1998, Lockwood et al. 1998, Norman
et al. 2001, Shen et al. 2005). Inhibin A levels were
reported to be lower in the follicular ﬂuid of PCOS
follicles compared with control follicles, and there were
no differences in levels of activin A and inhibin B levels
(Magofﬁn & Jakimiuk 1998). Activin has been pre-
viously shown to increase theca and granulosa cell
proliferation (Miro & Hillier 1996, Duleba et al. 2001).
In vitro studies using primary cultures of theca cells
from PCOS ovaries produced more androgens than
normal controls, had higher levels of steroid intermedi-
ates produced during steroidogenesis and had higher
levels of STAR, LHR, CYP17 and CYP11A expression
than in size-matched control follicles (Gilling-Smith
et al. 1994, Nelson et al. 1999, Wickenheisser et al. 2000,
Jakimiuk et al. 2001, Nelson et al. 2001). Ovaries from
PCOS women have also been shown to have 1.5-fold
higher expression of betaglycan than controls that
would enhance inhibin binding and ability to block
activin action, whereas no difference in activin receptor
(types IA, IB, IIA and IIB) expression wasdetected (Zhu
et al. 2010). These alterations in inhibin and activin
concentrations coupled with increased thecal layers
may allow increased androgen production in PCOS
patients, caused not by an active excess secretion, but by
a reduction in the local inhibition of androgen
production by the reduced exposure to activins.
In conclusion, our present studies have conﬁrmed
that the biological effects of activin on theca cell
androgen production are inhibitory, whereas inhibin
acts in an opposing manner by causing an increase in
the production of androgens. Furthermore, these
effects of activin are modulated through the Smad
signaling pathway that results in decreased levels of
STAR and 3b-HSD gene expression. The studies also
show that inhibin appears to act almost exclusively by
blocking the inhibitory action of activins, a concept
supported by the similar responses of increased
androgen production when activin action was blocked
by the activin receptor blocker SB-431542, the activin-
binding protein follistatin and the Smad2/3 signaling
pathway by Smad7. All the results also support the novel
concept that theca cells themselves produce activins,
and potentially BMPs which autoregulate androgen
production locally. As follicles develop and acquire
aromatase, they require more androgen precursor,
and this is induced by increased production of inhibin
by the granulosa cells, which then act to negate the
suppressive effects of thecal, and granulosa cell activins,
and BMPs. Therefore, inhibin does not stimulate
androgen production, but acts to remove the effects
of the inhibitor, activin, on suppressing CYP17 and
3b-HSD, thus allowing increased androgen production.
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